Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Another piece in place for Ligand

Saturday's announcement by Ligand Pharmaceuticals Inc. that it has raised $32.5 million in a subscription unit offering marks the completion of a series of transactions that have moved LGND from an early stage company

Read the full 347 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers